Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Inhibition of Von Willebrand Factor (VWF) by ARC1779 Normalizes Von Willebrand Factor/FVIII Levels and Corrects Thrombocytopenia in VWD Type 2b Patients,

Petra Jilma-Stohlawetz, MD, Paul Knoebl, MD, Ingrid Pabinger, MD, James Gilbert, MD, Robert G. Schaub, PhD, Bernd Jilma, MD

Blood (2011) 118 (21): 3377.

https://doi.org/10.1182/blood.V118.21.3377.3377

Published: 2011

Journal Articles

Investigation Into the Mechanism of Action and Binding Site of BAX 499, An Aptamer Against Tissue Factor Pathway Inhibitor

Emily K. Waters, PhD, Ryan M. Genga, Heather A. Thomson, Robert G. Schaub, PhD, Jeffrey C. Kurz, PhD, Kathleen E. McGinness, PhD

Blood (2011) 118 (21): 1214.

https://doi.org/10.1182/blood.V118.21.1214.1214

Published: 2011

Journal Articles

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

Emily K. Waters, Ryan M. Genga, Michael C. Schwartz, Jennifer A. Nelson, Robert G. Schaub, Karen A. Olson, Jeffrey C. Kurz, Kathleen E. McGinness

Blood (2011) 117 (20): 5514–5522.

https://doi.org/10.1182/blood-2010-10-311936

Published: 2011

Includes: Supplemental data

Journal Articles

Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease

Diana R. Gutsaeva, James B. Parkerson, Shobha D. Yerigenahally, Jeffrey C. Kurz, Robert G. Schaub, Tohru Ikuta, C. Alvin Head

Blood (2011) 117 (2): 727–735.

https://doi.org/10.1182/blood-2010-05-285718

Published: 2011

Includes: Supplemental data

Journal Articles

TFPI Antagonist Aptamer ARC19499 Is a Procoagulant In Vitro and In Vivo.

Kathleen E. McGinness, PhD, Emily K. Waters, PhD, Ryan M. Genga, Karen A. Olson, PhD, Jennifer A. Nelson, PhD, Jeffrey C. Kurz, PhD, Robert G. Schaub, PhD

Blood (2010) 116 (21): 1134.

https://doi.org/10.1182/blood.V116.21.1134.1134

Published: 2010

Journal Articles

Single-Stranded Oligonucleotide Binding to P-Selectin Inhibits Adhesion of Sickle Red Blood Cells and Leukocytes to Endothelial Cells in Sickle Cell Model Mice: Novel Therapeutics for Vaso-Occlusive Episodes.

Diana Gutsaeva, PhD, James Parkerson, Robert G Schaub, PhD, Jeffrey Kurz, Alvin Head, MD

Blood (2009) 114 (22): 1545.

https://doi.org/10.1182/blood.V114.22.1545.1545

Published: 2009

Journal Articles

Evaluation of a Novel Anti-P-Selectin Aptamer ARC5690 On Venous Inflammation Following Acute Venous Thrombosis.

Jose Antonio Diaz, MD, Patrick A Lester, DVM, Jeffrey C Kurz, PhD, Shirley K Wrobleski, BS, LVT, Angela E Hawley, BS, Robert E Sigler, DVM, PhD, Thomas W Wakefield, MD, Robert G Schaub, PhD, Daniel Myers, DVM, MPH, DACLAM

Blood (2009) 114 (22): 3599.

https://doi.org/10.1182/blood.V114.22.3599.3599

Published: 2009

Journal Articles

An Aptamer Antagonist of Tissue Factor Pathway Inhibitor Improves Coagulation in Hemophilia A and FVIII Antibody-Treated Plasma.

Emily K. Waters, PhD, Jeffrey C. Kurz, PhD, Ryan Genga, Jennifer A Nelson, PhD, Kathleen E. McGinness, PhD, Robert G. Schaub, PhD

Blood (2009) 114 (22): 544.

https://doi.org/10.1182/blood.V114.22.544.544

Published: 2009

Journal Articles

The Anti Von Willebrand Factor Aptamer ARC1779 Prevents the Desmopressin-Induced Thrombocytopenia in VWD Type 2B.

Petra Paulinska, MD, Bernd Jilma, MD, Christa Firbas, MD, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD

Blood (2008) 112 (11): 3374.

https://doi.org/10.1182/blood.V112.11.3374.3374

Published: 2008

Journal Articles

Crystal Structure of Von Willebrand Factor (VWF) A1 Domain in Complex with Aptamer ARC1172, An Inhibitor of VWF-Platelet Binding

Ren-Huai Huang, PhD, David Fremont, PhD, Elodee A Tuley, John L Diener, PhD, Robert G Schaub, PhD, J. Evan Sadler, MD, PhD

Blood (2008) 112 (11): 257.

https://doi.org/10.1182/blood.V112.11.257.257

Published: 2008

Journal Articles

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

Chri sta Firbas, MD, Bernd Jilma, MD, Patricia G Wagner, Renta Hutabarat, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD

Blood (2008) 112 (11): 2298.

https://doi.org/10.1182/blood.V112.11.2298.2298

Published: 2008

Journal Articles

Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs

Karen E. Russell, Eva H. N. Olsen, Robin A. Raymer, Elizabeth P. Merricks, Dwight A. Bellinger, Marjorie S. Read, Bonita J. Rup, James C. Keith, Jr, Kyle P. McCarthy, Robert G. Schaub, Timothy C. Nichols

Blood (2003) 102 (13): 4393–4398.

https://doi.org/10.1182/blood-2003-05-1498

Published: 2003

Journal Articles

Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP)

Eva H. N. Olsen, Arlene S. McCain, Elizabeth P. Merricks, Thomas H. Fischer, Ivy M. Dillon, Robin A. Raymer, Dwight A. Bellinger, Scot A. Fahs, Robert R. Montgomery, James C. Keith, Jr, Robert G. Schaub, Timothy C. Nichols

Blood (2003) 102 (2): 436–441.

https://doi.org/10.1182/blood-2003-01-0290

Published: 2003

Journal Articles

Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models

Cécile V. Denis, Kyubum Kwack, Simin Saffaripour, Srinivas Maganti, Patrick André, Robert G. Schaub, Denisa D. Wagner

Blood (2001) 97 (2): 465–472.

https://doi.org/10.1182/blood.V97.2.465

Published: 2001

Journal Articles

Vaccines With Interleukin-12–Transduced Acute Myeloid Leukemia Cells Elicit Very Potent Therapeutic and Long-Lasting Protective Immunity

Kyriaki Dunussi-Joannopoulos, Kathlene Runyon, Jamie Erickson, Robert G. Schaub, Robert G. Hawley, John P. Leonard

Blood (1999) 94 (12): 4263–4273.

https://doi.org/10.1182/blood.V94.12.4263

Published: 1999

NARROW

Inhibition of Von Willebrand Factor (VWF) by ARC1779 Normalizes Von Willebrand Factor/FVIII Levels and Corrects Thrombocytopenia in VWD Type 2b Patients,

Investigation Into the Mechanism of Action and Binding Site of BAX 499, An Aptamer Against Tissue Factor Pathway Inhibitor

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease

TFPI Antagonist Aptamer ARC19499 Is a Procoagulant In Vitro and In Vivo.

Single-Stranded Oligonucleotide Binding to P-Selectin Inhibits Adhesion of Sickle Red Blood Cells and Leukocytes to Endothelial Cells in Sickle Cell Model Mice: Novel Therapeutics for Vaso-Occlusive Episodes.

Evaluation of a Novel Anti-P-Selectin Aptamer ARC5690 On Venous Inflammation Following Acute Venous Thrombosis.

An Aptamer Antagonist of Tissue Factor Pathway Inhibitor Improves Coagulation in Hemophilia A and FVIII Antibody-Treated Plasma.

The Anti Von Willebrand Factor Aptamer ARC1779 Prevents the Desmopressin-Induced Thrombocytopenia in VWD Type 2B.

Crystal Structure of Von Willebrand Factor (VWF) A1 Domain in Complex with Aptamer ARC1172, An Inhibitor of VWF-Platelet Binding

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs

Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP)

Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models

Vaccines With Interleukin-12–Transduced Acute Myeloid Leukemia Cells Elicit Very Potent Therapeutic and Long-Lasting Protective Immunity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only